Idiopathic Pulmonary Fibrosis clinical trials at UCSD
3 in progress, 0 open to eligible people
Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sorry, not yet accepting patients
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
La Jolla, California and other locations
Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Sorry, not currently recruiting here
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
La Jolla, California and other locations
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Sorry, in progress, not accepting new patients
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
San Diego, California and other locations
Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include Gordon Yung, MD.
Last updated: